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ARATHYROID CARCINOMA IS a rare endocrine malig-
nancy. It accounts for <1% of cases of sporadic primary
hyperparathyroidism (PHPT) and is usually associated with
more severe clinical manifestations than its much more
common benign counterpart, parathyroid adenoma.
(1–3) Its
course is typically indolent but progressive. The diagnosis
of malignancy is often made only when local recurrence or
metastases occur, because the histology of parathyroid tu-
mors can be equivocal or frankly misleading.
(4) Most pa-
tients with recurrent disease ultimately succumb to the ef-
fects of hypercalcemia rather than to direct tumor invasion
or distant metastases. A complete resection of all malignant
tissue at the time of initial surgery allows for the greatest
likelihood of a cure. Clinical clues to the possibility of a
parathyroid cancer, therefore, should lead the surgeon to an
aggressive initial operative approach. In the last decade,
greater knowledge of the molecular pathogenesis of para-
thyroid carcinoma has led to the development of diagnostic
markers that show promise, particularly when the histology
is ambiguous.
(2,3) Moreover, there is hope that greater un-
derstanding of the pathogenesis of parathyroid cancer will
lead to the development of new therapeutic strategies for
advanced, inoperable disease. This review focuses on the
more recent advances in parathyroid carcinoma, particu-
larly its molecular pathogenesis, diagnosis, and manage-
ment.
EPIDEMIOLOGY
To date, >400 cases of parathyroid carcinoma have been
reported.
(5) It is usually a sporadic disease, but familial
cases have been described. The largest series comes from
the National Cancer database.
(6) In most series of PHPT,
parathyroid carcinoma accounts for <1% of all cases, but an
incidence as high as 5% has been reported.
(1,7,8) The use of
varying criteria for its pathologic diagnosis is most likely the
reason why later studies have shown higher incidence rates.
In contrast to benign parathyroid disease, where women
predominate over men by a ratio of 3–4:1, parathyroid can-
cer occurs with equal frequency in both sexes. The age at
diagnosis is 10 yr earlier than the typical age when the
benign form of PHPT presents (mid-40s versus mid-50s).
ETIOLOGY
The etiology of parathyroid carcinoma is largely un-
known. A potential role for prior neck irradiation is less
clear than in the development of benign parathyroid dis-
ease.
(9–13) Rarely, parathyroid carcinoma has been re-
ported in patients with longstanding secondary hyperpara-
thyroidism.
(14,15) In the few such cases, it is unclear whether
the currently accepted pathological criteria of parathyroid
malignancy were met. Parathyroid carcinoma has also been
reported in hereditary syndromes of hyperparathyroid-
ism,
(16–19) particularly in hyperparathyroidism-jaw tumor
(HPT-JT) syndrome,
(20) a rare autosomal disorder, in
which as many as 15% of patients will have malignant para-
thyroid disease. Because cystic changes are common, this
disorder has also been referred to as cystic parathyroid ad-
enomatosis.
(21) In HPT-JT, ossifying fibromas of the max-
illa and mandible are seen in 30% of cases. Less commonly,
kidney lesions, including cysts, polycystic disease, hamarto-
mas, or Wilm’s tumors, can be present.
(22) Parathyroid car-
cinoma has also been reported in familial isolated hyper-
parathyroidism.
(17,23) Recently, parathyroid carcinoma, as
defined pathologically, has been reported in multiple endo-
crine neoplasia type 1 (MEN1) syndrome and with somatic
MEN1 mutations.
(24–26) However, recurrent parathyroid
disease in MEN1 may mimic, but not actually be caused by,
malignancy. Only one case of parathyroid carcinoma has
been reported in the MEN2A syndrome.
(27)
PATHOGENESIS
Oncogenes and tumor suppressor genes have been linked
to parathyroid carcinomas, especially those involved in the
control of the cell cycle. Examples include retinoblastoma
(Rb), p53, breast carcinoma susceptibility (BRCA2), and cy-
clin Dl/parathyroid adenomatosis gene 1 (PRAD1)
genes.
(28,29) To date there is no definitive evidence for a
primary role of these genes in parathyroid carcinoma, al-
though altered expression of these gene products may par-
ticipate in the process of malignant transformation.
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JO807427 1869 1880 DecemberAfter the report of Cryns et al.,
(30) showing loss of Rb
protein expression in parathyroid carcinoma, the absence of
this protein in parathyroid tumors was proposed as a tool
for the diagnosis of parathyroid malignancy. Since then,
however, conflicting results have been reported by other
investigators in terms of whether Rb gene alterations are
specific for parathyroid cancer.
(31–33) Moreover, Shattuck
et al.
(34) failed to detect microdeletions, insertions, or point
mutations in the coding and promoter regions of the Rb
gene in parathyroid carcinomas.
The HPT-JT syndrome has provided the best evidence
for a defined gene in parathyroid cancer. The gene is known
now as HRPT2 but other terms have been used, such as
CDC73 and Clorf 28.
(22) Evidence points to a strong asso-
ciation between HRPT2 mutations, the gene responsible
for HPT-JT, and parathyroid carcinoma.
(35–37) Parathyroid
carcinoma occurs with higher frequency in HPT-JT than in
sporadic PHPT (15% versus <1%). Similar germline muta-
tions occur in a subset of kindreds with familial isolated
hyperparathyroidism.
(22,35,37–44) The role of the HRPT2
gene in the pathogenesis of sporadic parathyroid carcinoma
was shown by Howell et al.
(35) and Shattuck et al.
(36) in
2003. In the former study,
(35) HRPT2 mutations were de-
tected in 4 of 4 sporadic parathyroid carcinomas and in 0 of
25 sporadic parathyroid adenomas. In the later study,
(36)
HRPT2 mutations were found in 10 of 15 patients with
apparently sporadic parathyroid carcinoma. Cetani et
al.
(37,45) identified HRPT2 mutations in 9 of 11 parathyroid
carcinomas but in 0 of 4 sporadic atypical adenomas. Most
of the mutations are of the nonsense form and are predicted
to result in lack of or reduced protein expression of the
encoded parafibromin protein (see below) (Fig. 1). The
prevalence of HRPT2 mutations in sporadic parathyroid
carcinomas may be as high as 76.6% (Table 1). Thus, the
strong association between HRPT2 mutation and parathy-
roid malignancy suggests that this molecular event is in-
volved in the pathogenesis of most sporadic parathyroid
carcinomas. Of particular interest is the demonstration that
germline mutations were identified in about one third of
subjects.
(36,37,45) This finding suggests that a subset of pa-
tients with apparently sporadic parathyroid carcinomas
may have the HPT-JT syndrome or a variant. Inactivating
mutations of noncoding or regulatory regions could also be
implicated in the pathogenesis of sporadic parathyroid car-
cinoma and might be present in those without alterations in
the coding regions of the gene. A recent study by Haven et
al.
(46) found HRPT2 inactivating mutations in only 4 of 28
(15%) cases of parathyroid carcinomas. Two mutations
were germinal. These tumors were classified as malignant
on the basis of pathological criteria alone without the re-
quirement for malignant behavior. In this study, the exons
that harbor 85% of all known mutations (1, 2, and 7) were
completely screened. The low mutation frequency could be
explained in part by the fact that not all exons could be
completely evaluated because of the nature of the formalin-
fixed–embedded tissue. Another mechanism of HRPT2
gene inactivation, methylation of the promoter, has been
reported in 2 of 11 parathyroid carcinomas.
(47)
HRPT2 mutations are found, but only rarely, in sporadic
benign parathyroid adenomas.
(22,35,37,48) The overall preva-
lence among the 167 cases of benign disease in which an
HRPT2 mutation has been sought is only 1.8%, or even
lower 1/120 (0.8%) if the cases from Carpten et al.,
(22)
which were selected for cystic features, are excluded. These
observations indicate that HRPT2 mutations have a very
limited, if any, role in the pathogenesis of typical sporadic
adenomas.
HRPT2 encodes a protein of 531 amino acids called para-
fibromin (parathyroid disease and fibro-osseous lesions)
that is evolutionarily conserved
(22) and similar in homology
(54%) to a protein of Saccharomyces cerevisiae known as
Cdc73. Cdc73 is a component of yeast RNA polymerase
FIG. 1. HRPT2 mutations in sporadic parathyroid carcinomas. Mutations are designed according to the format generally used in the
HRPT2 literature with single-letter amino acid codes. Mutations in bold are germinal.
(36,37,45,46) *This mutation has been found in three
unrelated kindreds.
(36,37)
MARCOCCI ET AL. 1870II/Paf1 complex, which is involved in the transcription elon-
gation and RNA processing pathways. A human counter-
part to the yeast Paf1 complex has been identified.
(49–51)
Parafibromin is mostly a nuclear protein with a functional
bipartite nuclear localization signal (NLS) at residues 125–
139 (nucleotides 373–417), which is evolutionary conserved
and critical for its nuclear localization.
(52–54) Specific
HRPT2 mutations, identified in HPT-JT or sporadic para-
thyroid carcinoma and predicted to truncate parafibromin
upstream of or within the NLS, disrupt nuclear localiza-
tion.
(53) Parafibromin is also localized to the nucleolus.
Three nucleolar localization signals at residues 76–92, 192–
194, and 393–409 have been identified.
(55)
The role of parafibromin as a tumor suppressor protein
comes from the observation that parathyroid tumors carry-
ing HRPT2 mutations are frequently associated with loss of
parafibromin expression or function. Transient overexpres-
sion of wildtype parafibromin in HEK-293 and NIH3T3
cells, but not its L64P mutant, which is implicated in para-
thyroid cancer, inhibited cell proliferation by blocking cyc-
lin D1 expression.
(56) Thus, it is conceivable that, after bi-
allelic HRPT2 inactivation, the inhibitory effect of
parafibromin on cyclin D1 activity is lost, leading to neo-
plastic transformation in susceptible tissue such as parathy-
roid glands.
(56) Direct evidence of the anti-proliferative ef-
fect of parafibromin was first reported by Zhang et al.
(57) in
several cell lines by showing that some disease-associated
HRPT2 mutant constructs abolished the ability of wildtype
parafibromin to suppress colony formation. Iwata et al.
(58)
have recently confirmed that the transient overexpression
of parafibromin inhibited the growth of HEK293 or
NIH3T3 cells. Conversely, in cell lines expressing the large
TABLE 1. HRPT2 GENE ANALYSES IN PARATHYROID CARCINOMAS*
Author ID HRPT2 mutation Type of HRPT2 mutation LOH at HRPT2
† Effect on parafibromin
Howell et al.
(35)‡
2119 Y54X ND No Stop codon
1798 76delA ND No Frame shift with stop codon
2077 IVS6–1delG Somatic No Frame shift with stop codon
Y55X Somatic Stop codon
10977 165delC ND Yes Frame shift with stop codon
Shattuck et al.
(36)
1 82del4 Somatic No Frame shift with stop codon
732delT Somatic Frame shift with stop codon
2 E24X Somatic No Stop codon
746delT Somatic Frame shift with stop codon
3 R76X Somatic No Stop codon
4 39delC Somatic Yes Stop codon
5 23TGCG>GTG Somatic No Frame shift with stop codon
6 R222X Germ line Results uninformative Stop codon
7 373insA Germ line No Frame shift with stop codon
8 679insAG Germ line No Frame shift with stop codon
Y54X Somatic Stop codon
9 16delA ND ND Frame shift with stop codon
1230delC ND Frame shift with stop codon
10 60del10 ND ND Frame shift with stop codon
R234X ND Stop codon
11 Wildtype — ND —
12 Wildtype — No —
13 Wildtype — No —
14 Wildtype — No —
15 Wildtype — ND —
Cetani et al.
(37,45)
1 Wildtype — Yes —
2 R234X Germ line No Stop codon
3 195insT Somatic Yes Frame shift with stop codon
4 R9X Somatic Yes Stop codon
5 195insA Somatic Yes Frame shift with stop codon
6 R9X Somatic Yes Stop codon
7 R234X Germ line Yes Stop codon
8 E24X Somatic Yes Stop codon
9 R139X Germ line No Stop codon
10 Wildtype — No —
11 L61X Somatic No Stop codon
* Modified from Reference 3.
† A tumor was scored positive for loss of heterozygosity (LOH) if HRPT2 intragenic markers showed LOH.
‡ In this study, LOH was assessed using microsatellite markers flanking the HRPT2 gene.
ND, not determinable because germline DNA was not available.
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overexpression of parafibromin increased cell proliferation.
Thus, in LT-expressing cells, parafibromin could favor tu-
morigenesis.
The existence of a connection between parafibromin
function and components of the transcription machinery is
further supported by the fact that the Drosophila ortholog
of human parafibromin, hyrax, binds to -catenin/armadillo
and is required for the nuclear transduction of the Wnt/
Wingless pathway.
(59) Finally, Lin et al.
(53) showed that
wildtype, but not NLS-mutant, parafibromin promotes ap-
optosis in transfected cells. Inhibition of endogenous para-
fibromin expression by RNA interference decreases the
basal and cytotoxic-induced apoptosis.
These observations establish the central role of parafi-
bromin in the control of the cell cycle and subsequently in
determining cell fate and promoting tumorigenesis. The re-
lationship of parafibromin with the complex network of
nuclear components merits further study.
PATHOLOGY
Parathyroid carcinomas are typically large (>3 cm), ir-
regular, grayish-white, hard tumors often adherent tena-
ciously to adjacent tissues.
(2,4,60) The finding of gross infil-
tration of contiguous structures strongly suggest the
diagnosis of carcinoma. The histological criteria of parathy-
roid carcinoma are difficult to define and identify. Schantz
and Castleman
(61) in 1973 established a set of criteria, in-
cluding thick fibrous bands, mitotic activity, and vascular
and capsular invasion. Generally, neoplastic cells (usually
chief cells) are arranged in a lobular pattern and separated
by dense trabeculae, with mitotic figures. Invasion of the
capsule is rather common and, less frequently (10–15%),
vascular invasion also occurs.
(60) Capsular invasion is char-
acterized by a “tongue-like” protrusion through the collag-
enous fibers and should be distinguished from pseudoinva-
sion, because of “trapping” of tumor cells within the
capsule, which can be found in adenoma.
(2,62) The criteria
of vascular invasion have been differently defined accord-
ing to whether capsular vessels or vessels in the surrounding
tissues are involved.
(2,62,63) Partial attachment of tumor
cells to the wall of the vascular channel or thrombosis
should also be present.
(2,63)
Because metastatic behavior is rare at presentation,
(64)
the diagnosis of parathyroid cancer on the basis of the
above morphologic criteria may be difficult at the time of
the initial operation. Many of the features described above,
such as adherence to surrounding tissues, fibrous bands,
trabecular growth, and mitosis, are not pathognomonic of
malignancy because they can also be found in parathyroid
adenomas. The diagnostic value of capsular and vascular
invasion is still debated. Some authors regard vascular in-
vasion as virtually diagnostic of malignancy.
(2,64) Thus, con-
troversy and diagnostic uncertainties still exist.
(2,62,63) The
distinction between benign and malignant parathyroid tu-
mors is very hard and rarely made at initial histology. In-
deed, in a large series of patients with metastatic parathy-
roid cancers, as many as 50% were initially classified as
benign tumors.
(65) A full discussion of the pathology of
parathyroid cancer is beyond the scope of this review.
In an attempt to improve diagnostic accuracy, other his-
tological approaches have been studied, but none has yet
proven clear diagnostic value.
(33,66–72) However, the high
rate of HRPT2 abnormalities in parathyroid carcinomas
has paved the way for the development of new diagnostic
tools (HRPT2 mutational status and/or parafibromin im-
munostaining) of potential utility, particularly in cases with
equivocal initial histology (see below). Investigation of pa-
tients who have clinically and biochemically severe, but
pathologically benign, parathyroid disease, and those with
malignant pathology despite mild clinical features will help
to elucidate further the utility of these diagnostic tools as
markers for parathyroid carcinoma.
CLINICAL PRESENTATION
The clinical manifestations of parathyroid carcinoma are
primarily caused by the effects of markedly elevated serum
PTH levels and hypercalcemia rather than by the local in-
filtration or distant metastases.
(1,2)
The typical clinical picture is characterized by signs and
symptoms of severe hypercalcemia, with renal involvement
(nephrocalcinosis, nephrolithiasis, impaired renal function)
in up to 80% of patients, and bone involvement (osteitis
fibrosa cystica, subperiosteal resorption, “salt and pepper”
skull, diffuse osteopenia) in up to 90%.
(1) On physical ex-
amination, up to 76% of patients with parathyroid carci-
noma have a palpable neck mass.
(1) Renal colic is a fre-
quent presenting complaint. Other symptoms include
muscle weakness, fatigue, depression, nausea, polydipsia
and polyuria, bone pain, and fractures. Recurrent severe
pancreatitis, peptic ulcer disease, and anemia can also oc-
cur. None of these features is pathognomonic of malig-
nancy. In the majority of cases, the diagnosis of parathyroid
carcinoma is made only in retrospect when hypercalcemia
recurs because of local spread of tumor or distant metasta-
ses. In some patients with parathyroid cancer, a PTH moi-
ety, different from intact PTH(1-84), is produced.
(73) The
clinical implications of this finding in parathyroid carci-
noma await additional studies.
Rarely, parathyroid carcinomas are nonfunctional.
(43,74)
They can be misdiagnosed as thyroid or thymic carcinoma
because of locally advanced disease (palpable neck mass,
dysphagia, hoarseness caused by laryngeal nerve palsy). Im-
munohistochemistry for PTH, thyroglobulin, thyroid tran-




The occurrence of metastases is the only unequivocal
criterion of malignancy that is generally accepted, but they
usually occur late in the course of the disease.
At initial presentation, despite clinical features suggest-
ing malignancy, it can be a challenge to differentiate be-
tween hyperparathyroidism caused by parathyroid carci-
noma and that caused by its much more common benign
MARCOCCI ET AL. 1872counterpart. Because better outcomes are associated with
complete resection of the tumor at the time of initial sur-
gery, it is important to establish the correct diagnosis at the
time the patient presents.
Features that might lead to suspect a parathyroid cancer
in a patients with PHPT are listed here and in Table 2.
● Male sex: there is no sex preference, whereas the fe-
male:male ratio in PHPT favors women by a ratio of
3–4:1
● Relatively young age: the average age of a patient with
parathyroid cancer is 50 yr, about 10 yr younger than
the usual patient with benign PHPT.
● Markedly elevated serum calcium and PTH: Serum
calcium levels are within 1 mg/dl above the upper nor-
mal limit in most patients with parathyroid adenomas
and >14–15 mg/dl in most patients with parathyroid
carcinoma. PTH levels are markedly elevated in pa-
tients with parathyroid carcinoma and only slightly el-
evated in those with adenomas.
● Bone and renal involvement: the combination of both
renal and bone manifestations at the time of presen-
tation suggests the possibility of parathyroid carci-
noma. In benign PHPT, overt bone disease is unusual,
and concomitant skeletal and renal involvement is un-
common.
● Size and appearance of the parathyroid lesion: para-
thyroid carcinomas are usually >3 cm and may be pal-
pable. The tissue is hard and gray-white and adherent
to adjacent structures. Parathyroid adenomas are
smaller, dark brown, and firm but not hard.
Alkaline phosphatase activity is also higher in patients
with parathyroid carcinoma than in those with adenoma in
whom serum levels are generally close to the upper limit of
the normal range. - and -subunits of human chorionic
gonadotropin (hCG) may be elevated in patients with para-
thyroid cancer but not in those with benign tumors.
(75) Uri-
nary hCG levels were found to be elevated in a small group
of subjects with parathyroid carcinomas, in contrast to a
control group of patients with benign PHPT.
(76) In particu-
lar, the elevated hCG isotype was the hyperglycosolated
form of hCG that is specifically associated with malignancy
in trophoblastic and nontrophoblastic diseases. Moreover,
elevations of hCG might be predictive of complications
such as hip fracture and death.
When benign PHPT presents with markedly elevated se-
rum calcium concentrations and overt target organ involve-
ment, a clinical phenotype that was historically common but
is now infrequently seen in most countries, the clinical dis-
tinction between benign and malignant disease may be dif-
ficult. It is preferable to have a high index of suspicion
particularly when concomitant kidney and bone disease are
present than to miss the opportunity for surgical cure by
failing to consider cancer in the differential diagnosis.
Acute PHPT, sometimes called “parathyroid crisis,”
shares many clinical features with parathyroid carcinoma.
In view of the marked elevations of serum calcium and
PTH that are common in parathyroid crisis, parathyroid
cancer should be considered in any differential diagnosis of
this condition. Parathyroid cancer should also be consid-
ered in any hypercalcemic patient without a history of prior
neck surgery who presents with recurrent laryngeal nerve
palsy.
Aids to diagnosis by pathological examination
of tissue
Immunohistochemistry is used to improve the accuracy
of the diagnosis of parathyroid carcinoma. One approach
has involved the use of proliferation markers. Increased
labeling of cell cycle–associated antigens (Ki-67, cyclin D1)
has been shown in parathyroid carcinoma compared with
adenoma,
(66,68) but overlap among these tumor types has
limited the utility of this approach. Decreased expression of
p27, an inhibitor of cyclin-dependent kinase, and abnormal
galectin-3 expression have been shown in carcinomas. The
association between these abnormalities and high Ki-67 la-
beling has been suggested to increase the likelihood of ma-
lignancy.
(70,72)
Evaluation of HRPT2 gene abnormalities seems to be a
more promising diagnostic tool.
(77) Loss of heterozygosity
(LOH) or mutation at the HRPT2 gene and loss (total or
focal) of parafibromin staining have been reported in the
large majority of parathyroid carcinomas but very rarely in
adenomas
(45,78–81) (Fig. 2). To date, limited data are avail-
able in equivocal cases, where this technique would have
the greatest diagnostic utility (Table 3). It is important to
emphasize that the diagnostic potential of these tests hinges
on their common presence in parathyroid cancer and their
rarity in benign disease. Because benign parathyroid dis-
ease is so much more common than parathyroid cancer, a
test that has a detectable detection rate in benign parathy-
roid disease (even if low) would have limited clinical utility.
The positive predictive value of the test may be increased,
therefore, if the HRPT2 gene/parafibromin analysis is re-
stricted to cases that are equivocal. The combined findings
of negative parafibromin staining and HRPT2 gene abnor-
malities increase the likelihood of a malignancy.
(45,82)
Based on this reasoning, it seems appropriate to evaluate all
parathyroid tumors in which the diagnosis is uncertain for
abnormalities of both the HRPT2 gene and its product,
parafibromin.
NATURAL HISTORY AND SURVEILLANCE
Parathyroid carcinoma typically runs an indolent, albeit
progressive, course because the tumor has a rather low ma-
TABLE 2. CLINICAL FEATURES USEFUL IN THE DIFFERENTIAL
DIAGNOSIS BETWEEN BENIGN AND MALIGNANT
PRIMARY HYPERPARATHYROIDISM*
Benign Malignant
Female:male ratio 3–4:1 1:1
Average age (yr) 55 48
Serum calcium (mg/dl) 11.2 >14
Serum PTHP Mildly elevated Markedly elevated




* Modified from Reference 1.
PARATHYROID CARCINOMA 1873lignant potential. At initial presentation, very few patients
show involvement of regional lymph nodes (<5%) or dis-
tant sites (<2%).
(1,60) Parathyroid carcinoma recurs locally
and spreads to contiguous structures in the neck. Metasta-
ses occur late in the course of the disease with spread to
cervical nodes (30%) and lung (40%), followed in fre-
quency by liver metastases (10%). Rarely, distant metasta-
ses occur in bone, pleura, pericardium, and pancreas.
The identification of HRPT2 mutations in eight patients
with apparently sporadic parathyroid cancers as germline
events
(36,37,45,46) suggests that a subset of these patients
might have HPT-JT syndrome or variant thereof. This ob-
servation has implications for the management of recurrent
disease in parathyroid cancer. When a patient develops a
recurrence of parathyroid cancer, in addition to the likeli-
hood that the original carcinoma has progressed, a new
tumor should be carefully sought, because additional, dis-
crete parathyroid tumors can develop in patients with HPT-
JT syndrome. Surveillance for renal and jaw lesions is also
indicated. Moreover, the relatives of a patient with seem-
ingly sporadic parathyroid carcinoma carrying a germline
HRPT2 mutation are susceptible to the development of
parathyroid cancer or other manifestations of HPT-JT syn-
drome.
(43,44) In one such patient, a parathyroid cancer was
imaged early by neck ultrasonography in an individual who
had not yet become hypercalcemic.
(43) Therefore, monitor-
ing of family members with serum calcium determinations
and neck ultrasonography is warranted. As suggested by
Kelly et al.,
(44) surgery should be aimed at identifying and
examining all parathyroid glands and en bloc removal of
any abnormal tissue. A metal-clip marking the glands left in
situ may also be considered, anticipating the need for future
surgery. Because of parathyroid cancer in this setting has
incomplete penetrance (i.e., not all subjects harboring the
HRPT2 gene abnormality will express the disease), prophy-
lactic total parathyroidectomy is generally not recom-
mended. In those who do undergo complete parathyroid-
ectomy, autotransplantation of parathyroid tissue to the
forearm is not recommended to avoid the introduction of




Surgery is the only curative treatment for parathyroid
carcinoma and consists of complete resection of the primary
lesion at the time of initial operation.
(1,5) For this reason,
both preoperative suspicion and intraoperative recognition
are of great importance. Patients who present with features
suggestive of parathyroid carcinoma warrant thorough ex-
ploration of all four parathyroid glands, because parathy-
roid carcinoma has been reported to coexist along with
benign adenomas or hyperplasia.
(14) The most effective sur-
gical approach is en bloc resection.
(83,84) Tracheoesopha-
geal, paratracheal, and upper mediastinal lymph nodes
should be excised, but an extensive lateral neck dissection is
indicated only when there is spread to the anterior cervical
nodes.
When the diagnosis of parathyroid cancer is made after
FIG. 2. Immunohistochemical analysis of parafibromin expres-
sion. (Top) Normal parathyroid. A diffuse nuclear staining is pres-
ent in most parathyroid cells (×200). (Middle) Parathyroid ade-
noma. The majority of cells show a positive nuclear staining
(×400). (Bottom) Parathyroid carcinoma. Tumor cells show no
nuclear staining (×200). (Reproduced from Eur J Endocrinol
156:547–554 with permission from the European Society of En-
docrinology.)
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Fig 2 live 4/Cparathyroid surgery on the basis of pathology, as often hap-
pens, the management plan becomes more complex. If the
macroscopic characteristics of the tumor are typical of a
parathyroid carcinoma, and the pathology shows extensive
vascular or capsular invasion or if hypercalcemia persists,
further exploration of the neck can be considered after ap-
propriate localization studies (see below). The structures
surrounding the tumor should be excised as described
above. When telling histologic features are absent, the pa-
tient is normocalcemic and the diagnosis is only based on
equivocal pathology, immediate reoperation is not indi-
cated, because the simple complete resection of the tumor
may turn out to be curative. However, such patients should
be monitored closely with regular measurement of serum
calcium and PTH levels.
Despite a potentially curative resection, parathyroid car-
cinoma has a recurrence rate of >50%. Most recurrences
occur 2–3 yr after the initial operation, but this period is
variable, and a prolonged disease-free interval of as long
as 20 yr has been reported.
(1,85) Imaging studies should be
performed in all patients before reoperation. Fine-needle
aspiration of a suspicious lesion with measurement of PTH
in the eluate should be used with caution, if at all, to avoid
seeding the needle track with deposits of malignant
cells.
(86,87) If noninvasive imaging approaches are nega-
tive, arteriography and selective venous sampling for PTH
measurement may be useful. The management of recurrent
or metastatic parathyroid carcinoma is primarily surgi-
cal.
(1,5,83–85,88,89) Recurrences in the neck should be treated
with wide resections, including the regional lymph nodes
and other involved structures. Accessible distant metasta-
ses, particularly in the presence of localized metastatic dis-
ease, should also be excised, if possible.
(1,90) Even a small
tumor may produce a sufficient amount of PTH to cause
hypercalcemia. Although resection of single metastasis or
other foci of malignant tissue is rarely curative, their re-
moval may result in periods of normocalcemia ranging from
months to years.
(5) Decreasing tumor mass may also render
the patient’s hypercalcemia more amenable to medical
treatment.
Chemotherapy
Chemotherapy generally is disappointing. Several regi-
mens have been attempted (nitrogen mustard, vincristine,
cyclophosphamide, and actinomycin D, and adriamycin
alone or in combination with cyclophosphamide and 5-fluo-
rouracil), but none of them has proved to be effective.
(91,92)
At this time, chemotherapy has no role in the management
of patients with parathyroid carcinoma.
Radiotherapy
With the exception of a single report
(91) of an apparent
cure (10 yr) in a patient with tumor invasion of trachea,
TABLE 3. SUMMARY OF PARAFIBROMIN IMMUNOHISTOCHEMISTRY IN PARATHYROID TUMORS
Authors Parathyroid lesions
Parafibromin staining HRPT2 mutations
Cases (n) Negative* (%) Positive Cases (n) Positive
Tan et al.
(74) Carcinomas 52 50
† 2N D
Equivocal carcinomas 6 3 3 ND
HPT-JT adenomas 9 8
‡ 1N D
Sporadic adenomas 73 0 73 ND
Gill et al.
(75) Carcinomas 11 8 3
§ 22
HPT-JT adenomas 4 3 1
¶ 33
Sporadic adenomas 79 0 79 ND
Cetani et al.
(37,45) Carcinomas 11 11 0 11 9
Equivocal carcinomas 4 2 2 4 0
Sporadic adenomas 22 1** 21 22 1
Juhlin et al.
(76,77) Carcinomas 22 15
†† 75 5
Equivocal carcinomas 11 5
‡‡ 61 1
Sporadic adenomas
§§ 41 3 38
¶¶ 43
Total Carcinomas 96 84 (87.5) 12 (12.5) 18 16
Equivocal carcinomas 21 10 (47.6) 11 (52.4) 5 1
HPT-JT adenomas 13 11 (84.6) 2 (13.4) 3 3
Adenomas 215 4 (1.9) 211 (98.1) 26 4
* Unless otherwise stated, tumors classified as negative showed a complete loss of parafibromin staining.
† Twenty-six tumors showed a diffuse loss (i.e., absence of nuclear staining in all tumor) and 24 a focal loss (i.e., absence of nuclear staining in variably
sized regions).
‡ Six tumors showed a diffuse loss and two showed a focal loss.
§ Two tumors had weak staining (staining of ∼50% of parathyroid cells) and one sample had strong staining (diffuse staining of >95% of parathyroid
cells).
¶ The tumor had weak staining.
** The tumor carries a somatic HRPT2 mutation.
†† Fourteen tumors had a partial loss and one had a complete loss.
‡‡ The tumors had partial loss.
§§ The tumors were selected for the presence of cystic features.
¶¶ Three tumors showed both nuclear staining together with weaker cytoplasmic expression, and one tumor only exhibited cytoplasmic expression.
ND, not done.
PARATHYROID CARCINOMA 1875radiation therapy has little, if any, effect in invasive para-
thyroid cancer.
(85) Recent reports have suggested the use of
irradiation as adjuvant therapy. The Mayo Clinic reported a
disease-free survival at a median follow-up period of 60 mo
in four patients who received postoperative adjuvant radio-
therapy.
(93) The MD Anderson Cancer Center experience
also suggests a lower local recurrence rate if adjuvant ra-
diation was given after surgery, independent of the type of
operation and the disease stage.
(94,95)
Management of hypercalcemia
When parathyroid carcinoma has became widely meta-
static and surgical options are exhausted, clinical manage-
ment becomes a matter of controlling the hypercalce-
mia.
(96) Saline infusion and loop diuretics are often used,
but in the majority of cases, drugs that inhibit bone resorp-
tion are needed. Potent intravenous bisphosphonates
(pamidronate and zoledronate) may transiently control hy-
percalcemia, but patients frequently become refractory to
them. Plicamicin is effective, but the response is transient,
and repeated courses may be associated with toxicity. Oc-
treotide, the long-acting somatostatin analog, has been re-
ported to inhibit PTH secretion in two cases of metastatic
parathyroid carcinoma.
(97,98)
Anti-PTH immunotherapy showed promise in two recent
case reports.
(99–101) Dendritic cell immunotherapy may also
be applicable to induce a T-cell immune response.
(102)
Another approach is to target the parathyroid calcium-
sensing receptor (CaSR). Calcimimetics, allosteric modula-
tors of the CaSR, directly reduce parathyroid cell hormone
secretion by binding to sites that increase the receptors’
affinity for calcium.
(103) Thus, sensitivity to extracellular
calcium is enhanced. A first-generation calcimimetic,
R-568, was used for 2 yr in a patient with metastatic para-
thyroid cancer with controlled hypercalcemia.
(104) R-568
has been replaced by cinacalcet, a more potent second-
generation agent with a longer half-life and more predict-
able hepatic metabolism. In benign PHPT, cinacalcet nor-
malizes serum calcium and partially reduces PTH
concentrations for up to 3 yr.
(105)
Recently, the results of a multicenter study of cinacalcet
in 29 patients with inoperable parathyroid carcinoma were
published.
(106) The primary endpoint of the study was the
proportion of patients experiencing a 1-mg/dl reduction
in serum calcium from baseline at the end of the titration
phase. Secondary endpoints included changes from baseline
in serum calcium, plasma PTH, bone turnover markers, and
health-related quality of life variables. The dose of cinacal-
cet in this study was titrated from 30 mg twice daily (a dose
that might be effective in benign PHPT) up to 90 mg four
times daily as required to lower serum calcium levels. Du-
ration of treatment ranged from 1 to 1051 days (mean, 328
± 306 days). Cinacalcet effectively reduced hypercalcemia
in about two thirds of patients with inoperable parathyroid
carcinoma (Fig. 3). In the responders (18 of 29 patients),
serum calcium levels declined from 15.0 ± 0.5 to 11.2 ± 0.3
mg/dl (p < 0.001), with the greatest responses seen in those
patients with the highest levels of serum calcium at study
entry. It was of interest that the marked reductions in serum
calcium were not accompanied by a similar fall in circulat-
ing PTH. PTH levels reached a nadir 4 h after drug admin-
istration, but the decline was not pronounced, nor was it
FIG. 3. Reduction in serum calcium concentration in parathyroid cancer with cincalcet. Subjects were given cinacalcet in increasing
doses, up to 90 mg four times daily, during the titration phase. The average serum calcium fell from 14.5 ± 0.4 to 12.4 ± 0.4 mg/dl (p
  0.001). (Adapted from Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA,
Klassen P, Bilezikian JP 2007 Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
J Clin Endocrinol Metab 92:3803–3808, Copyright 2007, The Endocrine Society.)
MARCOCCI ET AL. 1876sustained. Although hypotheses abound, the reason for the
discrepancy in calcium and PTH response to cinacalcet re-
mains unclear at this time. Nausea and vomiting were the
most common adverse events. Reported in more than one
half of all patients receiving cinacalcet at these doses, these
symptoms necessitated discontinuation of drug in some
cases. Serious adverse events, including fracture and death,
were not considered to be drug related. Instead, they were
expected consequences of the patients’ longstanding, often
widely metastatic, underlying disease. There are no data
suggesting that cinacalcet alters the course of the parathy-
roid cancer itself. Therefore, this agent should not be intro-
duced to control hypercalcemia in a patient with a meta-
static lesion that is accessible and amenable to surgical
extirpation. However, the data do suggest that cinacalcet is
useful in reducing calcium levels, and is tolerated in many
patients at cumulative doses up to 360 mg/d. Furthermore,
unlike other options for treatment of hypercalcemia, this
agent can be used in patients with the renal impairment so
common in patients with longstanding parathyroid cancer.
Cinacalcet therefore represents an important new option
for management of intractable hypercalcemia in patients
with inoperable disease.
PROGNOSIS
The prognosis of parathyroid carcinoma is quite variable.
No single characteristic correlates with outcome. The best
prognosis depends on early recognition and complete exci-
sion of the tumor at initial surgery. The mean time to re-
currence is usually 3 yr, although intervals of up to 20 yr
have been reported.
(1,65) Once the tumor recurs, complete
cure is unlikely, although prolonged survival is still common
with palliative surgery. Five-year survival rates vary from
40% to 86%. The National Cancer Database survey re-
ported a 10-yr survival of ∼49%,
(107) and the MD Andersen
Cancer Center reported survival rates of 85% and 77% at 5
and 10 yr, respectively.
(89) The National Surveillance, Epi-
demiology, and End Results database recently reported a
10-yr survival of 67.8%.
(108)
SUMMARY
The best opportunity to cure parathyroid carcinoma is to
diagnose it before or at the time of parathyroid surgery and
for the tumor to be completely removed at the time of the
initial operation. Because the diagnosis is often not clear at
the time of presentation, recent attempts to distinguish be-
tween benign and malignant disease both by genetic and
immunohistological analyses are promising. The disease is
indolent but progressive. Attempts to remove local recur-
rences and distant metastases can provide short- and long-
term control. Other therapeutic approaches with chemo-
therapy and radiotherapy are not helpful. Available
medical therapy targets the consequence of the disease (hy-
percalcemia) rather than the disease itself.
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